Jourdan Andersson, a graduate student at the University of Texas Medical Branch, and others on the research team screened a library of 780 FDA-approved therapeutics and tested them against Yersinia pestis, a bacteria that is becoming antibiotic-resistant.
Here are three points:
1. As many as 94 drugs were found to be significantly effective in a cell-culture system when tested against Yersinia pestis.
2. After further screening, three drugs, trifluoperazine, doxapram and amoxapine were used in a mouse model and found to be effective in treating Yersinia pestis.
3. In further experiments, trifluoperazine was successfully used to treat Salmonella enterica and Clostridium difficile infections.
More articles on quality & infection control:
Customer service is source of patient online complaints — 4 notes
Elizabethkingia makes its way into Illinois, infects 10 residents — 5 things to know
CDC, OSHA issues guidelines to help prevent Zika infections — 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.